Biopharmaceuticals: Reference Products and Biosimilars to Treat Inflammatory Diseases

Therapeutic Drug Monitoring

Volumn 39, Issue 4, 2017, Pages 308-315

  Gils, Ann ^a   Bertolotto, Antonio ^b   Mulleman, Denis ^c   Bejan Angoulvant, Theodora ^c   Declerck, Paul J ^a  

^a DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

^b AOU San Luigi   (Italy)

^c UNIVERSITÉ DE TOURS   (France)

Author keywords

biopharmaceuticals; biosimilar; health economics; inflammatory diseases

Indexed keywords

BIOSIMILAR AGENT; MONOCLONAL ANTIBODY; ANTIINFLAMMATORY AGENT; BIOLOGICAL PRODUCT;

ARTICLE; CHRONIC DISEASE; CLINICAL TRIAL (TOPIC); DRUG COST; HUMAN; IMMUNE RESPONSE; INFLAMMATORY DISEASE; PHARMACEUTICS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ANIMAL; ECONOMICS; INFLAMMATORY BOWEL DISEASE; PROCEDURES; PSORIASIS; RHEUMATIC DISEASE; THERAPEUTIC EQUIVALENCE; TREATMENT OUTCOME;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BIOLOGICAL PRODUCTS; BIOPHARMACEUTICS; BIOSIMILAR PHARMACEUTICALS; CLINICAL TRIALS AS TOPIC; HUMANS; INFLAMMATORY BOWEL DISEASES; PSORIASIS; RHEUMATIC DISEASES; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME;

EID: 85013630591     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0000000000000385     Document Type: Article

References (38)

1. Walsh G, Jefferis R. Post-translational modifications in the context of therapeutic proteins. Nat Biotechnol. 2006;24:1241-1252.
2. Farley AR, Link AJ. Identification and quantification of protein posttranslational modifications. Methods Enzymol. 2009;463:725-763.
3. Crommelin DJ, Storm G, Verrijk R, et al. Shifting paradigms: biopharmaceuticals versus low molecular weight drugs. Int J Pharm. 2003;266:3-16.
4. Dreesen E, Gils A, Vermeire S. Pharmacokinetic modeling and simulation of biologicals in inflammatory bowel disease: the dawning of a new era for personalized treatment. Curr Drug Targets. 2016. In press.
5. Sauerborn M, Brinks V, Jiskoot W, et al. Immunological mechanism underlying the immune response to recombinant human protein therapeutics. Trends Pharmacol Sci. 2010;31:53-59.
6. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495-497.
7. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances WHO 2009. Available at: http://www.who.int/medicines/services/inn/RevisedFinalStemBook2006.pdf. Accessed November 3, 2016.
8. Reichert JM. Antibodies to watch in 2016. MAbs. 2016;8:197-204.
9. Higel F, Seidl A, Sörgel F, et al. N-glycosylation heterogeneity and the influence on structure, function and pharmacokinetics of monoclonal antibodies and Fc fusion proteins. Eur J Pharm Biopharm. 2016;100:94-100.
10. Matsuda F, Ishii K, Bourvagnet P, et al. The complete nucleotide sequence of the human immunoglobulin heavy chain variable region locus. J Exp Med. 1998;188:2151-2162.
11. van der Valk ME, Mangen MJ, Severs M, et al. Evolution of costs of inflammatory bowel disease over two years of follow-up. PLoS One. 2016;11:e0142481.
12. Medina F, Plasencia C, Goupille P, et al. Current practice for therapeutic drug monitoring of biopharmaceuticals in rheumatoid arthritis. Ther Drug Monit. 2017;39:364-369.
13. Medina F, Placensia C, Goupille P, et al. Current practice for therapeutic drug monitoring of biopharmaceuticals in spondyloarthritis. Ther Drug Monit. 2017;39:360-363.
14. Caldano M, Raoul W, Rispens T, et al. Drug Efficacy monitoring in pharmacotherapy of multiple sclerosis with biological agents. Ther Drug Monit. 2017;39:350-355.
15. Detrez I, Van Stappen T, Arranz MD, et al. Current practice for therapeutic drug monitoring of biopharmaceuticals in inflammatory bowel disease. Ther Drug Monit. 2017;39:344-349.
16. Hermans C, Harrans P, Segaert S, et al. Current practice of therapeutic drug monitoring of biopharmaceuticals in psoriasis patients. Ther Drug Monit. 2017;39:356-359.
17. Di Sabatino A, Liberato L, Marchetti M, et al. Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel disease. Intern Emerg Med. 2011;6(suppl 1):17-27.
18. Gils A. Combining therapeutic drug monitoring with biosimilars, a strategy to improve efficacy of biologicals for treatment of IBD at an affordable cost. Dig Dis. 2017;35:61-68.
19. Guideline on the Investigation of Bioequivalence. London, United Kingdom: European Medicines Agency; 2010. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2010/01/WC500070039.pdf. Accessed November 3, 2016.
20. Declerck PJ. Biosimilar monoclonal antibodies: a science-based regulatory challenge. Expert Opin Biol Ther. 2013;13:153-156.
21. Guideline on Similar Biological Medicinal Products. 2014. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2014/10/WC500176768.pdf. Accessed July 19, 2016.
22. Farfan-Portet MI, Gerkens S, Lepage-Nefkens I, et al. Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures? Eur J Health Econ. 2014;15:223-228.
23. Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. MAbs. 2015;7:9-14.
24. Moorkens E, Jonker-Exler C, Huys I, et al. Overcoming barriers to the market access of biosimilars in the European Union: the case of biosimilar monoclonal antibodies. Front Pharmacol. 2016;7:193.
25. Nonproprietary Naming of Biological Products 2015. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM459987.pdf. Accessed November 3, 2016.
26. Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72: 1605-1612.
27. Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72:1613-1620.
28. Jung YS, Park DI, Kim YH, et al. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter study. J Gastroenterol Hepatol. 2015;3: 1705-1712.
29. Jahnsen J, Detlie TE, Vatn S, et al. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: a Norwegian observational study. Expert Rev Gastroenterol Hepatol. 2015;9(suppl 1): 45-52.
30. Gecse KB, Lovász BD, Farkas K, et al. Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases: a prospective, multicentre, nationwide cohort. J Crohns Colitis. 2016;10: 133-140.
31. Declerck P, Mellstedt H, Danese S. Biosimilars-terms of use. Curr Med Res Opin. 2015;31:2325-2330.
32. Smits LJ, Derikx LA, de Jong DJ, et al. Clinical outcomes following a switch from Remicade® to the biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort study. J Crohns Colitis. 2016;10:1287-1293.
33. Ben-Horin S, Yavzori M, Benhar I, et al. Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima. Gut. 2015;65:1132-1138.
34. Gils A, Van Stappen T, Dreesen E, et al. Harmonization of infliximab and anti-infliximab assays facilitates the comparison between originators and biosimilars in clinical samples. Inflamm Bowel Dis. 2016;22:969-975.
35. Emery P, Vencovský J, Sylwestrzak A, et al. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2017;76:51-57.
36. Emery P, Vencovský J, Ghil J, et al. Response to: "comparing the immunogenicity of the etanercept biosimilar SB4 with the innovator etanercept: another consideration" by Marshall, et al. Ann Rheum Dis. 2016;75:e38.
37. Marshall L, Hickling T, Bill D, et al. Comparing the immunogenicity of the etanercept biosimilar SB4 with the innovator etanercept: another consideration. Ann Rheum Dis. 2016;75:e37.
38. Emery P, Vencovský J, Kang JW, et al. Confirmation on the immunogenicity assay used in the SB4 phase III study: response to the comments by Meacci, et al. Ann Rheum Dis. 2016;75:e40.